REFERENCES
1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus
Disease 2019 in China. The New England journal of medicine
2020;382:1708-20.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track
COVID-19 in real time. Lancet Infect Dis 2020;20:533-4.
4. CDC. ACIP Evidence to Recommendations for Use of Pfizer-BioNTech
COVID-19 Vaccine under an Emergency Use Authorization. CDC.gov2020.
5. Herper M. FDA grants authorization to Moderna’s Covid-19 vaccine, the
second in the U.S. STAT News2020.
6. Johnson J. Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate
Unanimously Recommended for Emergency Use Authorization by U.S. FDA
Advisory Committee. JnJ.com2021.
7. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. In:
NIH, ed.2021.
8. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights
into atopic dermatitis. The Journal of clinical investigation
2004;113:651-7.
9. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower
respiratory illness is increased in asthma and related to virus load and
Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A
2008;105:13562-7.
10. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in
atopic dermatitis: pathogenic aspects and clinical management. J Allergy
Clin Immunol 2003;112:667-74.
11. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma
protective against COVID‐19? Allergy 2020.
12. Leung DY. Atopic dermatitis: the skin as a window into the
pathogenesis of chronic allergic diseases. J Allergy Clin Immunol
1995;96:302-18; quiz 19.
13. Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective
cytokines in COVID-19 patients reflect viral load and lung injury.
National Science Review 2020.
14. Luo W, Zhang JW, Zhang W, Lin YL, Wang Q. Circulating Levels of
IL‐2, IL‐4, TNF‐α, IFN‐γ and C reactive protein Are Not Associated with
Severity of COVID‐19 Symptoms. Journal of Medical Virology 2020.
15. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal
immunological misfiring in severe COVID-19. Nature 2020;584:463-9.
16. Fuxench ZCC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in
America Study: a cross-sectional study examining the prevalence and
disease burden of atopic dermatitis in the US adult population. Journal
of Investigative Dermatology 2019;139:583-90.
17. GUIDANCE ON THE USE OF IMMUNOSUPPRESSIVE AGENTS. 2020.
18. Rheumatology ACo. COVID-19 Clinical Guidance for Adult Patients with
Rheumatic Diseases. Rheumatology.org2020.
19. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
Risk of hospitalization and death from COVID-19 infection in patients
with chronic plaque psoriasis receiving a biologic treatment and renal
transplant recipients in maintenance immunosuppressive treatment.
Journal of the American Academy of Dermatology 2020;83:285-7.
20. Holcomb ZE, Santillan MR, Morss-Walton PC, et al. Risk of COVID-19
in dermatologic patients receiving long-term immunomodulatory therapy.
Journal of the American Academy of Dermatology 2020;83:1215-8.
21. Neurath MF. Covid-19 and immunomodulation in IBD. Gut
2020;69:1335-42.
22. Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in
Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J
Allergy Clin Immunol Pract 2020;8:516-26.
23. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab
progressively improves systemic and cutaneous abnormalities in patients
with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-72.
24. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of
dupilumab in patients with severe chronic rhinosinusitis with nasal
polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two
multicentre, randomised, double-blind, placebo-controlled,
parallel-group phase 3 trials. Lancet 2019;394:1638-50.
25. He H, Olesen CM, Pavel AB, et al. Tape-strip proteomic profiling of
atopic dermatitis on dupilumab identifies minimally invasive biomarkers.
Frontiers in Immunology 2020;11:1768.
26. Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M.
Dupilumab and COVID-19: What should we expect? Dermatol Ther
2020:e13502.
27. Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety
of dupilumab in severe atopic dermatitis and infection of Covid-19: two
case reports. J Eur Acad Dermatol Venereol 2020;34:e303-e4.
28. Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic
infection in a patient under treatment with dupilumab. J Eur Acad
Dermatol Venereol 2020.
29. Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P. Management
of adult patients with severe atopic dermatitis treated with dupilumab
during COVID-19 pandemic: A single-center real-life experience. Dermatol
Ther 2020:e13765.
30. Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G.
Safety of dupilumab in atopic patients during COVID-19 outbreak. J
Dermatolog Treat 2020:1-2.
31. Carugno A, Raponi F, Locatelli A, et al. No evidence of increased
risk for COVID‐19 infection in patients treated with Dupilumab for
atopic dermatitis in a high‐epidemic area‐Bergamo, Lombardy, Italy.
Journal of the European Academy of Dermatology and Venereology 2020.
32. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19
severity and fatality: a structured literature review. Infection
2020:1-14.
33. Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered
patients with COVID-19. The Lancet 2021;397:173-5.
34. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic
burden of hospitalized COVID-19 patients in the United States. Journal
of Medical Economics 2021:1-.
35. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive
activation of T(H)2/T(H)22 cytokines and selective epidermal proteins
characterizes acute and chronic atopic dermatitis. J Allergy Clin
Immunol 2012;130:1344-54.
36. Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with
either omalizumab or an inhaled corticosteroid boost to prevent fall
asthma exacerbations. Journal of Allergy and Clinical Immunology
2015;136:1476-85.
37. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients
with atopic dermatitis modulates activated inflammatory pathways and
reverses epidermal pathology. J Allergy Clin Immunol 2014;133:1626-34.
38. Tintle S, Shemer A, Suarez-Farinas M, et al. Reversal of atopic
dermatitis with narrow-band UVB phototherapy and biomarkers for
therapeutic response. J Allergy Clin Immunol 2011;128:583-93 e1-4.
39. Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads
to progressive anti-inflammatory effects in the skin of patients with
moderate-to-severe atopic dermatitis. J Allergy Clin Immunol
2016;138:169-78.